

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CF PharmTech, Inc. **長風藥業股份有限公司**

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2652)

VOLUNTARY ANNOUNCEMENT **ACCEPTANCE OF IND APPLICATION FOR ICF004 BY THE NMPA**

This announcement is made by CF PharmTech, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the latest research and development of the Group.

INTRODUCTION

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the investigational new drug (“**IND**”) application (the “**Application**”) for ICF004 (the “**Product**”), the Company’s internally developed inhaled dry powder candidate, has been accepted by the National Medical Products Administration of the People’s Republic of China (“**NMPA**”). The relevant information is hereby announced as follows:

Product name	:	ICF004 (Inhaled Dry Powder)
Application type	:	New drug application
Registration category	:	Class 1 chemical drug candidate
Acceptance number	:	CXHL2600132/CXHL2600133
Applicant	:	Changfeng Suyue Pharmaceutical (Guangzhou) Co., Ltd. (a subsidiary of the Company), the Company

ICF004 is intended for the treatment of progressive fibrosing interstitial lung disease, a disease area that includes life-threatening indications such as idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. ICF004 uses an inhaled dry powder delivery route designed to deliver the drug directly to lung lesion areas, thereby increasing local pulmonary exposure while minimizing systemic exposure to the extent possible, in pursuit of a more favorable balance between efficacy and safety.

STRATEGIC SIGNIFICANCE

In preclinical studies completed to date, ICF004 demonstrated a differentiated distribution profile following inhaled administration, characterized by high lung tissue exposure and low systemic exposure. These findings support a development strategy centered on enhancing target-organ delivery efficiency while minimizing systemic burden through localized administration. In addition, anti-fibrotic activity trends observed in relevant preclinical models provide preliminary supportive evidence for further clinical development; however, whether these findings translate into clinical efficacy and safety benefits in humans remains to be verified in future clinical trials.

The acceptance of the Application represents a significant milestone in the Company's innovative drug development efforts, and further reflects the translational potential of its complex respiratory formulation and precision delivery platform. The Company believes that progress in the ICF004 program demonstrates its ability to integrate complex formulations, delivery systems, and device engineering to target unmet clinical needs, establishes a methodological foundation for future respiratory innovation programs, and underscores the Company's long-term potential in delivery-enabled innovative drug development beyond its core complex formulation business.

The Group will maintain active communication with the NMPA and advance subsequent clinical activities in accordance with regulatory requirements.

RISK WARNING

The acceptance of the Application represents an administrative step in the review process and does not constitute marketing approval. The Product is subject to further review and assessment by the NMPA, and there is no assurance that the Application will be approved. Due to the high-tech, high-risk and high-value-added characteristics of pharmaceutical products, there are substantial risks and uncertainties in the process of drug research, development and commercialization. Given such risks and uncertainties, **shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

ABOUT THE COMPANY

As a global innovator in inhalation drug delivery technology, CF PharmTech, Inc. is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs. The Company is not only a specialist in the development of complex inhalation formulations with high barriers to entry, but also a platform-based innovative pharmaceutical company with integrated capabilities spanning device engineering, precision drug delivery, global regulatory filing and commercialization.

Leveraging its fully self-developed, globally integrated end-to-end capabilities – from exhalation-powered nasal spray delivery systems and liposomal inhalation technology to siRNA nucleic acid delivery platforms – the Company is systematically advancing its proprietary innovative pipeline for the markets in China, the United States and Europe. Its therapeutic areas encompass respiratory diseases (including asthma, chronic obstructive pulmonary disease and bronchiectasis) and nasal diseases (including allergic rhinitis and chronic rhinosinusitis), with strategic expansion into pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections and central nervous system disorders, as the Company advances precision drug delivery via the nose-to-brain pathway.

The Company has established an extensive multi-dimensional commercialization network in China and, through its globally compliant manufacturing systems and deepening international presence, is steadily advancing towards its goal of becoming a global innovative pharmaceutical enterprise.

By order of the Board
CF PharmTech, Inc.
長風藥業股份有限公司
Dr. LIANG Bill Wenqing

Chairperson, Executive Director and Chief Executive Officer

Hong Kong, February 24, 2026

As at the date of this announcement, the Board comprises Dr. LIANG Bill Wenqing, Dr. LI LI BOVET, Dr. LI Qi and Ms. ZHU Yuyu as executive Directors, Mr. CHEN Penghui, Mr. CAI Lei and Dr. YI Hua as non-executive Directors, and Dr. JIN Jian, Ms. WANG Lijuan, Mr. WEI Shirong and Mr. IP Wang Hoi as independent non-executive Directors.